How long does it take to lower ldl cholesterol
Pro Research Analysisby 
Searched over 200M research papers
Consensus Meter
How Long Does It Take to Lower LDL Cholesterol?
Lowering low-density lipoprotein (LDL) cholesterol is crucial for reducing the risk of cardiovascular diseases. Various treatments, including statins and newer medications like PCSK9 inhibitors, have been studied for their efficacy in lowering LDL cholesterol levels. This article synthesizes findings from multiple studies to provide a comprehensive understanding of how long it takes to lower LDL cholesterol.
Rapid LDL Cholesterol Reduction with PCSK9 Inhibitors
Evolocumab
Evolocumab, a PCSK9 inhibitor, has shown significant efficacy in rapidly lowering LDL cholesterol levels. In the FOURIER trial, patients achieved substantial reductions in LDL cholesterol within just 4 weeks of treatment. The study found a monotonic relationship between lower LDL cholesterol concentrations and reduced cardiovascular events, with no significant safety concerns over a median follow-up of 2.2 years. Another study, the EVOPACS trial, demonstrated that evolocumab, when initiated during the in-hospital phase of acute coronary syndromes (ACS), reduced LDL cholesterol levels from 3.61 mmol/L to 0.79 mmol/L within 8 weeks.
Inclisiran
Inclisiran, another PCSK9 inhibitor, has also been effective in lowering LDL cholesterol. A phase 2 trial showed that a single dose of inclisiran produced sustained reductions in LDL cholesterol over 84 days, with the most significant reductions observed at 180 days. Patients receiving two doses of inclisiran achieved up to a 52.6% reduction in LDL cholesterol levels.
Alirocumab
Alirocumab, yet another PCSK9 inhibitor, has been studied for its long-term efficacy. In a randomized trial, patients receiving alirocumab experienced a 62% reduction in LDL cholesterol levels at 24 weeks, with the effect remaining consistent over 78 weeks.
Statins and Intensive LDL Cholesterol Lowering
Standard and Intensive Statin Therapy
Statins are a well-established treatment for lowering LDL cholesterol. A meta-analysis of 14 randomized trials involving 90,056 participants found that statin therapy could reduce LDL cholesterol by an average of 1.09 mmol/L within the first year, with significant reductions in major vascular events observed within the first year and greater benefits in subsequent years. Another meta-analysis of 26 trials with 170,000 participants showed that more intensive statin regimens produced a further 15% reduction in major vascular events compared to less intensive regimens, with each 1 mmol/L reduction in LDL cholesterol reducing the annual rate of major vascular events by just over a fifth.
Efficacy in Older Patients
Lipid-Lowering in Older Adults
A systematic review and meta-analysis focusing on older patients (aged 75 years and older) found that LDL cholesterol-lowering therapies were as effective in reducing cardiovascular events in older patients as in younger ones. The study reported a 26% reduction in major vascular events per 1 mmol/L reduction in LDL cholesterol, with benefits observed for each component of the composite endpoint, including cardiovascular death, myocardial infarction, stroke, and coronary revascularization.
Conclusion
The time it takes to lower LDL cholesterol varies depending on the treatment used. PCSK9 inhibitors like evolocumab and inclisiran can produce significant reductions within weeks to months, while statins also show substantial efficacy within the first year of treatment. Both types of therapies are effective in reducing cardiovascular events, with no significant safety concerns reported. These findings underscore the importance of early and intensive LDL cholesterol-lowering strategies to mitigate cardiovascular risk.
Sources and full results
Most relevant research papers on this topic